NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).

Employees

Sector

Biotechnology & Medical Research

Calendar

06-23 - Significant Split/Dividend

More about the company

Quotes

Date	Price	Change	Volume
26-06-12	0.000200 €	0.00%	29,537,737
26-06-11	0.000200 €	0.00%	9,750,208
26-06-10	0.000200 €	0.00%	10,188,340
26-06-09	0.000200 €	0.00%	33,209,750
26-06-08	0.000200 €	0.00%	16,013,118

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-06-12 EDT			5-day change	1st Jan Change
0.000200 ^EUR	0.00%		0.00%	-97.70%

02-10	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
11-20	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI

Market Cap	4.15K 4.8K 3.82K 3.58K 6.7K 456K 6.81K 45.11K 17.59K 222K 18.02K 17.63K 769K	P/E Ratio 2023 *	-	P/E Ratio 2024	-
Enterprise Value	-201K -233K -185K -173K -325K -22.11M -330K -2.19M -852K -10.76M -873K -855K -37.27M	EV / Sales 2023	-	EV / Sales 2024	-0.12x
Free-Float	1.27%	Yield 2023 *	-	Yield 2024	-

02-10	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
11-20	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-10-20	Neovacs S.A. announced that it expects to receive ?0.25 million in funding	CI
25-08-11	Neovacs S.A. announced that it has received ?0.25 million in funding from European High Growth Opportunities Manco S.A.	CI
25-04-29	Neovacs S.A. Auditor Raises 'Going Concern' Doubt	CI
25-04-29	Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-16	Neovacs S.A. announced a financing transaction	CI
25-02-04	Neovacs: consideration of delisting, share price surges
24-11-04	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-11-01	Tech's Tangled Path with Microsoft
24-06-17	Neovacs: collaboration agreement with CNRS
24-06-10	Neovacs: presents results from vaccine candidates
24-06-04	Néovavs: raises 200,000 euros through the issue of OCEANE-BSA bonds

05-22	Bourse : Richemont brille, Estée Lauder renonce à Puig, Kioxia grossit
05-22	L'IA reprend le leadership
05-04	Bourse : GameStop veut racheter Ebay, game over pour Spirit, Engie accélère dans l'éolien
05-04	Coup de théâtre ou coup d'épée dans l'eau ?
04-29	NEOVACS : Le projet VECT-PI sélectionné pour un financement dans le cadre de France 2030

NEOVACS Stock

Stocks

ALNEV

FR0014010856

Biotechnology & Medical Research

Valuation: NEOVACS

Chart: NEOVACS

Latest news : NEOVACS

News in other languages: NEOVACS

Quotes and Performance

Course Extremes

Managers and Directors: NEOVACS

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	0		0
1 month	0		0
Current year	0		0.03
1 year	0		4.2
3 years	0		1,000,000
5 years	0		1,000,000
10 years	0		1,000,000

Manager	Title	Age	Since
Hugo Brugière CEO	Chief Executive Officer	-	-
Alexandre Courtoux DFI	Director of Finance/CFO	-	2020-09-30
Laurent Reber CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Jean-Jacques Bertrand CHM	Chairman	87	2003-05-27
Baudouin Hallo BRD	Director/Board Member	-	2020-04-30
Hugo Brugière CHM	Chairman	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
21-02-26	Hugo Brugière	Sell	Chief Executive Officer	2,505,144	1.3796%
21-02-22	Hugo Brugière	Sell	Chief Executive Officer	1,108,947	0.6107%
21-02-22	Hugo Brugière	Sell	Chief Executive Officer	6,391,053	3.5196%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEOVACS	0.00%	0.00%	-99.99%	-100.00%	367K
LONZA GROUP AG	-0.35%	+0.97%	-15.96%	-12.73%	42.96B
REVOLUTION MEDICINES, INC.	+2.95%	+2.92%	+273.60%	+506.82%	31.73B
IQVIA HOLDINGS INC.	-1.07%	-2.40%	+12.52%	-15.50%	30.22B
BEONE MEDICINES AG	+1.68%	-1.91%	-4.19%	+24.27%	28.94B
CELLTRION, INC.	+4.09%	-1.98%	+11.99%	+17.37%	23.87B
MEDPACE HOLDINGS, INC.	-1.23%	+3.39%	+54.49%	+115.42%	13.57B
EUROFINS SCIENTIFIC SE	-0.40%	-1.29%	+6.06%	+7.59%	12.96B
ASCENDIS PHARMA A/S	+2.56%	+5.18%	-	-	13.39B
IONIS PHARMACEUTICALS, INC.	-0.68%	-1.84%	+105.25%	+75.62%	12.2B
Average	+0.75%	-0.64%	+38.20%	+68.76%	20.98B
Weighted average by Cap.	+0.92%	-1.08%	+54.16%	+95.54%

	2023	2024
Net sales	533K 618K 492K 460K 862K 58.7M 876K 5.8M 2.26M 28.57M 2.32M 2.27M 98.93M	434K 502K 400K 374K 701K 47.75M 712K 4.72M 1.84M 23.24M 1.89M 1.85M 80.48M
Net income	-8.74M -10.12M -8.06M -7.54M -14.13M -962M -14.35M -95.14M -37.09M -468M -37.99M -37.18M -1.62B	-32.91M -38.11M -30.33M -28.39M -53.21M -3.62B -54.03M -358M -140M -1.76B -143M -140M -6.1B
Net Debt	-237K -274K -218K -204K -382K -26.03M -388K -2.57M -1M -12.67M -1.03M -1.01M -43.86M	-205K -237K -189K -177K -332K -22.57M -337K -2.23M -870K -10.99M -891K -872K -38.04M

3 months	-81.82%
6 months	-98.02%
Current year	-97.70%